Sign in
HALO Stock Price, Chart, Stats & News
Halozyme Therapeutics, Inc.
Save
Halozyme Therapeutics, Inc. (HALO) does not currently pay a dividend.
12.81B
Market cap
20.15x
Current P/E
10.96x
Forward P/E
HALO chart
Fundamentals
Gross margin | 81.95% |
Operating margin | 58.45% |
Pretax margin | 33.43% |
Net margin | 22.69% |
Effective tax rate | 32.13% |
ROA | 12.55% |
ROE | 92.67% |
D/E | – |
Interest coverage ratio | 45.03x |
HALO valuation
P/E | 20.15x |
P/S | 5.21x |
P/B | 148.57x |
P/CF | 11.13x |
P/FCF | 11.28x |
P/OCF | 11.13x |
PEG | -0.49x |
EV multiple | 7.68x |
About
Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHANZE drug delivery platform, which utilizes a patented recombinant human hyaluronidase enzyme (rHuPH20). This innovative technology significantly enhances the subcutaneous (under-the-skin) administration of a diverse range of injectable medicines.
Similar securities
Based on sector and market capitalization
Report issue